Report of Foreign Issuer (6-k)
January 27 2020 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
For the month of January 2020
Commission File Number: 001-37643
KITOV PHARMA LTD.
(Translation of registrant’s name
into English)
One Azrieli Center, Round Tower,
132 Menachem Begin Road, Tel Aviv 6701101,
Israel
(Address of principal executive offices)
Indicate by check mark
whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Kitov
Pharma Ltd. (the “Company” or the “Registrant”) is announcing that on January 24, 2020, the Company
issued a press release, “Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219
in Combination with EGFR Inhibitors”, which is attached hereto as Exhibit 99.1.
This Form 6-K, including all exhibits hereto, is
hereby incorporated by reference into each of the Registrant’s Registration Statements
on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117 and 333-211477),
the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration
file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission
on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally
filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s
Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number
333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September
16, 2019 (Registration file number 333-233795) and the Registrant’s Registration Statement on Form F-3 filed with the Securities
and Exchange Commission on December 2, 2019 (Registration file number 333- 333-235327).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
KITOV PHARMA LTD.
|
|
|
|
January 26, 2020
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
CEO & Director
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024